메뉴 건너뛰기




Volumn 13, Issue 5, 2011, Pages 379-380

JAK inhibition in rheumatoid arthritis

Author keywords

Antagonist autoimmune; CP 690,550; Efficacy; Inhibition; Interleukin; JAK inhibitor; Methotrexate; Rheumatoid arthritis

Indexed keywords

JANUS KINASE 3; PLACEBO; TASOCITINIB;

EID: 80755133642     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-011-0196-4     Document Type: Short Survey
Times cited : (2)

References (5)
  • 1
    • 75749127860 scopus 로고    scopus 로고
    • Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690, 550, an orally active Janus kinase (JAK) inhibitor: Results from a randomised, double-blind, placebocontrolled trial
    • Coombs JH, Bloom BJ, Breedveld FC, et al. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690, 550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebocontrolled trial. Ann Rheum Dis. 2010;69:413-6.
    • (2010) Ann Rheum Dis. , vol.69 , pp. 413-416
    • Coombs, J.H.1    Bloom, B.J.2    Breedveld, F.C.3
  • 2
    • 77956156894 scopus 로고    scopus 로고
    • Safety and efficacy after 24 weeks dosing of oral JAK inhibitor CP-690, 550 in combination with methotrexate in patients with active rheumatoid arthritis
    • abstract
    • Kremer JM, Cohen S, Wilkinson B, et al: Safety and efficacy after 24 weeks dosing of oral JAK inhibitor CP-690, 550 in combination with methotrexate in patients with active rheumatoid arthritis. Arthritis Rheum 2009, 60(S719):1925 (abstract).
    • (2009) Arthritis Rheum. , vol.60 , Issue.S719 , pp. 1925
    • Kremer, J.M.1    Cohen, S.2    Wilkinson, B.3
  • 3
    • 77956134928 scopus 로고    scopus 로고
    • The oral JAK inhibitor CP-690, 550 in combination with methotrexate is efficacious, safe and well tolerated in Japanese patients with active rheumatoid arthritis with an inadequate response to MTX alone
    • Abstract presented at, Copenhagen, Denmark, June 10-13
    • Tanaka Y, Suzuki M, Nakamura H, et al: The oral JAK inhibitor CP-690, 550 in combination with methotrexate is efficacious, safe and well tolerated in Japanese patients with active rheumatoid arthritis with an inadequate response to MTX alone. Abstract presented at the European League Against Rheumatism, Copenhagen, Denmark, June 10-13, 2009.
    • (2009) The European League Against Rheumatism
    • Tanaka, Y.1    Suzuki, M.2    Nakamura, H.3
  • 4
    • 77956136075 scopus 로고    scopus 로고
    • Phase 2B dose ranging monotherapy study of the oral JAK inhibitor CP-690, 550 or adalimumab vs placebo in patients with active rheumatoid arthritis with an inadequate reponse to DMARDs
    • OP-0159, abstract
    • Kanik K, Fleschmann RM, Cutolo M, et al: Phase 2B dose ranging monotherapy study of the oral JAK inhibitor CP-690, 550 or adalimumab vs placebo in patients with active rheumatoid arthritis with an inadequate reponse to DMARDs. Ann Rheum Dis 2009, 68:123 OP-0159 (abstract).
    • (2009) Ann Rheum Dis. , vol.68 , pp. 123
    • Kanik, K.1    Fleschmann, R.M.2    Cutolo, M.3
  • 5
    • 77956165442 scopus 로고    scopus 로고
    • Inhibition of JAK kinases in patients with rheumatoid arthritis: Scientific rationale and clinical outcomes
    • Riese RJ, Krishnaswami S, Kremer J. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol. 2010;24:513-26.
    • (2010) Best Pract Res Clin Rheumatol. , vol.24 , pp. 513-526
    • Riese, R.J.1    Krishnaswami, S.2    Kremer, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.